Infectious Diseases in End-Stage Liver Disease Patients

Critical Care Nursing Clinics of North America

Volumn 22, Issue 3, 2010, Pages 291-307

  Mehta, Aneesh K ^a   Lyon, G Marshall ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacterial infections; Cirrhosis; Infection; Sepsis; Spontaneous bacterial peritonitis

Indexed keywords

EID: 77955322026     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccell.2010.04.002     Document Type: Review

References (73)

1. Chavez-Tapia N.C., Torre-Delgadillo A., Tellez-Avila F.I., et al. The molecular basis of susceptibility to infection in liver cirrhosis. Curr Med Chem 2007, 14(28):2954-2958.
2. Caly W.R., Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993, 18(3):353-358.
3. Navasa M. Bacterial infections in patients with cirrhosis: reasons, comments and suggestions. Dig Liver Dis 2001, 33(1):9-12.
4. Borzio M., Salerno F., Piantoni L., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001, 33(1):41-48.
5. Campillo B., Pernet P., Bories P.N., et al. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol 1999, 11(7):755-759.
6. Liu H., Zhang S., Yu A., et al. Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS. Bioorg Med Chem Lett 2004, 14(9):2339-2344.
7. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343(20):1467-1476.
8. Fukui H., Brauner B., Bode J.C., et al. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991, 12(2):162-169.
9. Diehl A.M., Yin M., Fleckenstein J., et al. Tumor necrosis factor-alpha induces c-jun during the regenerative response to liver injury. Am J Physiol Gastrointest Liver Physiol 1994, 267(4):G552-G561.
10. Rajkovic I.A., Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986, 6(2):252-262.
11. Clapperton M., Rolando N., Sandoval L., et al. Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure. Eur J Clin Invest 1997, 27(2):164-168.
12. Gomez F., Ruiz P., Schreiber A.D. Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994, 331(17):1122-1128.
13. Guarner C., Runyon B.A. Macrophage function in cirrhosis and the risk of bacterial infection. Hepatology 1995, 22(1):367-369.
14. Runyon B.A. Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis. Hepatology 1988, 8(3):632-635. [Erratum appears in Hepatology 1988 Sep-Oct;8(5):1184].
15. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008, 28(1):26-42.
16. Rimola A., Soto R., Bory F., et al. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 1984, 4(1):53-58.
17. Deschenes M., Villeneuve J- P. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 1999, 94(8):2193-2197.
18. Saab S., Hernandez J.C., Chi A.C., et al. Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol 2009, 104(4):993-1001.
19. Neill M.A., Carpenter C.C. Other pathogenic vibrios. Principles and practice of infectious diseases 2009, 2787-2790. Churchill Livingstone, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
20. Daniels Nicholas A., MacKinnon L., Bishop R., et al. Vibrio parahaemolyticus infections in the United States, 1973-1998. J Infect Dis 2000, 181(5):1661-1666.
21. Balter S., Hanson H., Kornstein L., et al. Vibrio parahaemolyticus infections associated with consumption of raw shellfish-three States, 2006. MMWR Morb Mortal Wkly Rep 2006, 55(31):854-856.
22. Dechet Amy M., Yu Patricia A., Koram N., et al. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997-2006. Clin Infect Dis 2008, 46(7):970-976.
23. Jones M.K., Oliver J.D. Vibrio vulnificus: disease and pathogenesis. Infect Immun 2009, 77(5):1723-1733.
24. Klontz K.C., Lieb S., Schreiber M., et al. Syndromes of Vibrio vulnificus infections. Ann Intern Med 1988, 109(4):318-323.
25. Janda J.M., Graves M. Capnocytophaga. Principles and practice of infectious diseases 2009, 2991-2994. Churchill Livingstone, Philadelphia. 7th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
26. Brenner D.J., Hollis D.G., Fanning G.R., et al. Capnocytophaga canimorsus sp. nov. (formerly CDC group DF-2), a cause of septicemia following dog bite, and C. cynodegmi sp. nov., a cause of localized wound infection following dog bite. J Clin Microbiol 1989, 27(2):231-235.
27. Janda J.M., Graves M.H., Lindquist D., et al. Diagnosing Capnocytophaga canimorsus infections. Emerg Infect Dis 2006, 12(2):340-342.
28. Deshmukh P.M., Camp C.J., Rose F.B., et al. Capnocytophaga canimorsus sepsis with purpura fulminans and symmetrical gangrene following a dog bite in a shelter employee. Am J Med Sci 2004, 327(6):369-372.
29. Oehler R.L., Velez A.P., Mizrachi M., et al. Bite-related and septic syndromes caused by cats and dogs. Lancet Infect Dis 2009, 9(7):439-447.
30. Bottone E.J. Yersinia enterocolitica: overview and epidemiologic correlates. Microbes Infect 1999, 1(4):323-333.
31. Brann O.S. Infectious complications of cirrhosis. Curr Gastroenterol Rep 2001, 3(4):285-292.
32. Reed Robert P., Robins-Browne Roy M., Williams Michele L. Yersinia enterocolitica peritonitis. Clin Infect Dis 1997, 25(6):1468-1469.
33. Guerrant Richard L., Van Gilder T., Steiner Ted S., et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001, 32(3):331-351.
34. Steinberg J.P., Burd E.M. Other gram-negative and gram-variable bacilli. Principles and practice of infectious diseases 2009, vol. 2:3016-3019. Churchill Livingstone, Philadelphia. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
35. Ko W.C., Lee H.C., Chuang Y.C., et al. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia. J Infect 2000, 40(3):267-273.
36. Llopis F., Grau I., Tubau F., et al. Epidemiological and clinical characteristics of bacteraemia caused by Aeromonas spp. as compared with Escherichia coli and Pseudomonas aeruginosa. Scand J Infect Dis 2004, 36(5):335-341.
37. Choi J.P., Lee S.O., Kwon H.H., et al. Clinical significance of spontaneous Aeromonas bacterial peritonitis in cirrhotic patients: a matched case-control study. Clin Infect Dis 2008, 47(1):66-72.
38. Wu C.J., Lee H.C., Chang T.T., et al. Aeromonas spontaneous bacterial peritonitis: a highly fatal infectious disease in patients with advanced liver cirrhosis. J Formos Med Assoc 2009, 108(4):293-300.
39. Jayaraj K., Di Bisceglie A.M., Gibson S. Spontaneous bacterial peritonitis caused by infection with Listeria monocytogenes: a case report and review of the literature. Am J Gastroenterol 1998, 93(9):1556-1558.
40. Nolla-Salas J., Almela M., Gasser I., et al. Spontaneous Listeria monocytogenes peritonitis: a population-based study of 13 cases collected in Spain. Am J Gastroenterol 2002, 97(6):1507-1511.
41. Bennett L. Listeria monocytogenes. Principles and practice of infectious diseases 2009, vol. 2:2707-2714. Churchill Livingstone, Philadelphia. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
42. Merle-Melet M., Dossou-Gbete L., Maurer P., et al. Is amoxicillin-cotrimoxazole the most appropriate antibiotic regimen for Listeria meningoencephalitis? Review of 22 cases and the literature. J Infect 1996, 33(2):79-85.
43. Soares-Weiser K., Brezis M., Tur-Kaspa R., et al. Antibiotic prophylaxis for cirrhotic patients with gastrointestinal bleeding. Cochrane Database Syst Rev 2002, 2. CD002907.
44. Gustot T., Durand F., Lebrec D., et al. Severe sepsis in cirrhosis. Hepatology 2009, 50(6):2022-2033.
45. Foreman M.G., Mannino D.M., Moss M. Cirrhosis as a risk factor for sepsis and death: analysis of the national hospital discharge survey. Chest 2003, 124(3):1016-1020.
46. Kumar A.M., Roberts D.M., Wood K.E.D., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
47. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118(1):146-155.
48. Campillo B., Dypeyron C., Richardet J.P. Epidemiology of hospital-acquired infections in cirrhotic patients: effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001, 127(3):443-450.
49. Qurishi N., Kreuzberg C., Luchters G., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362(9397):1708-1713.
50. Loguercio C., Federico A., Tuccillo C., et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005, 39(6):540-543.
51. Stadlbauer V., Mookerjee R.P., Hodges S., et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008, 48(6):945-951.
52. Besselink M.G.H., van Santvoort H.C., Buskens E., et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371(9613):651-659.
53. Fujita T. Probiotics for patients with liver cirrhosis. J Hepatol 2008, 49(6):1080-1081.
54. Advisory Committee on Immunization Practices Recommended adult immunization schedule: United States, 2010. Ann Intern Med 2010, 152(1):36-38.
55. Flechner S.M., Avery R.K., Fisher R., et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998, 66(12):1682-1688.
56. Gourishankar S., Wong W., Dorval M. Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is ganciclovir a superior agent to acyclovir?. Transplant Proc 2001, 33(1-2):1870-1872.
57. Winston D.J., Wirin D., Shaked A., et al. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995, 346(8967):69-74.
58. Subramanian A., Dorman S. Mycobacterium tuberculosis in solid organ transplant recipients. Am J Transplant 2009, 9(Suppl 4):S57-S62.
59. Mazurek G.H., Weis S.E., Moonan P.K., et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 2007, 45(7):837-845.
60. Mazurek G.H., Zajdowicz M.J., Hankinson A.L., et al. Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferon-gamma release assays. Clin Infect Dis 2007, 45(7):826-836.
61. Lee S.S., Chou K.J., Su I.J., et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of Quantiferon-TB Gold, Elispot, and tuberculin skin test. Infection 2009, 37(2):96-102.
62. Triverio P.A., Bridevaux P.O., Roux-Lombard P., et al. Interferon-gamma release assays versus tuberculin skin testing for detection of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 2009, 24(6):1952-1956.
63. Manuel O., Humar A., Preiksaitis J., et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007, 7(12):2797-2801.
64. Ponce de Leon D., Acevedo-Vasquez E., Alvizuri S., et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008, 35(5):776-781.
65. Stephan C., Wolf T., Goetsch U., et al. Comparing quantiferon-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008, 22(18):2471-2479.
66. Takahashi H., Shigehara K., Yamamoto M., et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007, 27(12):1143-1148.
67. Roland M.E., Barin B., Carlson L., et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008, 8:355-365.
68. Unos Center specific report Table 11 summary: 1 year patient survival, adult [PDF]. Available at:, Accessed January 28, 2010. http://www.ustransplant.org/csr/current/csrDefault.aspx.
69. Nakamura N., Tamaru S., Ohshima K., et al. Prognosis of HTLV-1-positive renal transplant recipients. Transplant Proc 2005, 37(4):1779-1782.
70. Fischer S.A., Avery R.K. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009, 9(Suppl 4):S7-S18.
71. The National Library of Medicine - National Institute of Health DailyMed. Available at:, Accessed March 6, 2010. http://dailymed.nlm.nih.gov/dailymed/.
72. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services Available at:, Accessed March 6, 2010. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
73. Wyles David L., Gerber John G. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005, 40(1):174-181.